Meeting
2023 ASCO Annual Meeting
Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF.
Authors
Seid Kebir
Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Seid Kebir , Lazaros Lazaridis , Teresa Schmidt , Christoph Oster , Martin Proescholdt , Peter Hau , Anca L. Grosu , Dietmar Krex , Ulrich Sure , Björn Scheffler , Christoph Kleinschnitz , Christoph Pöttgen , Martin Stuschke , Martin Glas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2050)
DOI
10.1200/JCO.2023.41.16_suppl.2050
Abstract #
2050
Poster Bd #
407
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon
Poster
2022 ASCO Annual Meeting
Phase IB trial of pegylated arginine deiminase (ADI-PEG 20) plus radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
First Author: John S. Bomalaski
Poster
2020 ASCO Virtual Scientific Program
INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.
First Author: David A. Reardon
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran